A
Apmonia Therapeutics
Biotech & Life Sciences · Reims, France · Founded 2019
Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies MoreLess
Apmonia Therapeutics is a pharmaceutical startup that specializes in the development of innovative cancer therapies. The company's team comprises of professionals from the fields of science, development, and business, all working together to transform groundbreaking scientific discoveries into practical medical solutions. Their primary clients are individuals suffering from various types of cancer, particularly those with high unmet medical needs.
The company operates in the pharmaceutical industry, specifically in the immuno-oncology sector. Immuno-oncology refers to the science of using the body's immune system to fight cancer. Apmonia Therapeutics' research and development platform is based on extracellular matrix biology, molecular modeling, and in-house screening processes. In simpler terms, they study how cells interact with their surroundings, model these interactions on a molecular level, and screen potential drug candidates in-house.
Their business model revolves around the development and commercialization of these drug candidates. Their lead program, AP-01, is a drug that targets TSP-1, a protein involved in tumor growth. By targeting this protein, the drug aims to inhibit tumor growth and provide a new treatment option for cancer patients.
The company generates revenue through the sale of its pharmaceutical products once they have demonstrated clinical efficacy. As a startup, they may also rely on funding from investors and grants for research and development.
In conclusion, Apmonia Therapeutics is a promising startup in the pharmaceutical industry, with a focus on innovative cancer therapies. Their unique approach to drug development, combined with their commitment to addressing unmet medical needs, positions them as a potential leader in the immuno-oncology sector.
Keywords: Apmonia Therapeutics, pharmaceutical startup, cancer therapies, immuno-oncology, extracellular matrix biology, molecular modeling, in-house screening, drug development, AP-01, tumor growth.
Company overview
Apmonia Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Reims, France
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 76.0
Valuation & funding
Apmonia Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2026 | $11M | $44M | Capital Grand Est · Business Angels Marne Ardennes · Capital Cell · Angels Santé | ↗ |
| GRANT✓Other financing | Apr 2024 | $3M | — | Région Grand Est · French Ministry of Economics and Finance · France 2030 | ↗ |
| GRANT✓Other financing | Mar 2024 | $2.4M | — | European Innovation Council | — |
| SEED✓Equity / VC | Sep 2022 | $2.8M | $11M | Bpifrance | ↗ |
| SEED✓Equity / VC | Feb 2022 | $4.4M | $18M | Finovam · Fondation Fournier-Majoie · Angels Santé · Capital Grand Est | — |
| ANGEL✓Equity / VC | Sep 2020 | Business Angels Marne Ardennes | — | ||
| GRANTOther financing | Feb 2020 | Undisclosed | — | ||
| SUPPORT PROGRAM✓Other financing | Oct 2019 | HEC Paris · HEC Challenge+ | — | ||
| SPINOUT✓Other financing | Apr 2019 | French National Centre for Scientific Research - CNRS · CNRS Innovation | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $11K | 0% | 20 |
| 2025 | $11K | 0% | 18 |
| 2024 | $11K | 0% | 19 |
| 2023 | $11K | 0% | 17 |
| 2022 | $11K | 0% | 9 |
| 2021 | $11K | 0% | — |
| 2020 | $11K | — | — |
Growth signals
Apmonia Therapeutics website traffic
Latest recorded traffic for Apmonia Therapeutics is 410 monthly website visits, up 20.6% over the last three months. Apmonia Therapeutics's team grew 11.1% over the past year.
Comparisons
Apmonia Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Apmonia Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Apmonia Therapeutics has talent and traffic
team presence
In the news
Latest news about Apmonia Therapeutics
Recent press, funding announcements, and product moves mentioning Apmonia Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Apmonia Therapeutics
An AI-synthesized read of the highest-engagement posts about Apmonia Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apmonia Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.